Patient P-02146

Synthetic patientMETA-24 · Day 175 · 65–74 · M · baseline S14Open companion preview

Therapy response

Unstable

Tolerance

Improving

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 74 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 79 GI-04 recommended — GI Support Protocol GI-04
Day 80 Patient declined — Not now
Day 93 ME-01 recommended — Monitoring Escalation ME-01
Day 94 Patient accepted — Started ME-01 in the companion
Day 97 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 74.

Primary contributors, last 14 days

Toxicity-11
GI instability+7
Nutritional resilience-5
Inflammatory activity-2
Treatment adherence-2

What helped?

GI Support Protocol GI-04Day 79
Declined by patient
Monitoring Escalation ME-01Day 93
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
87% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 34/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑65
- WearableResting HR 88 bpm
- Wearable614 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 73 and rising
- WearableSleep 5.6 h, below personal baseline
Inflammatory signalling ↓60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 63
- WearableHRV 16 ms, trending down
Drug metabolism and exposure ↑20
- BloodToxicity index 48

DNA

Fictional pharmacogenomic panel

CYP2D6 Rapid metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity

Microbiome

Shannon diversity 2.8 · butyrate capacity 34/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 16 ms
Sleep: 5.1 h
Steps: 1,750
Resting HR: 86 bpm

Daily log: GI score 73, nutritional resilience 30, adherence 42.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02571	49%	S11	ME-01	improved	43
P-02610	49%	S14	NP-02	no change	42
P-02582	48%	S14	ME-01	improved	45
P-02505	47%	S14	NP-02	improved	45
P-02057	45%	S14	GI-04	improved	47
P-02124	45%	S14	GI-04	no change	31
P-02506	45%	S14	SC-12	no change	32
P-02014	44%	S14	GI-04	improved	48
P-02594	44%	S20	—	—	45
P-02132	42%	S14	SC-12	improved	40
P-02224	42%	S14	NP-02	no change	33
P-02320	42%	S14	NP-02	improved	50